Caladrius Biosciences Inc Share Price Nasdaq
Equities
US1280581042
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-09 | Transcript : Lisata Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
05-09 | Lisata Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 24.2M 1.93B |
---|---|---|---|---|---|
Net income 2024 * | -26M -2.08B | Net income 2025 * | -30M -2.39B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.32
x | P/E ratio 2025 * |
-1.09
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.21% |
Latest transcript on Caladrius Biosciences Inc
1st Jan change | Capi. | |
---|---|---|
+18.47% | 47.02B | |
+48.77% | 41.86B | |
+0.61% | 41.76B | |
-4.27% | 28.8B | |
+11.71% | 26.05B | |
-21.82% | 19.15B | |
+3.73% | 12.55B | |
+28.22% | 12.34B | |
-4.44% | 11.82B |